Page 1

ORTHOFIX® NEWS RELEASE Orthofix Reports Third Quarter 2021 Results 11/5/2021 • Net sales of $ 112 million , an increase of 1.3 % over the prior year period • Double - digit growth over the prior year period for both global Spinal Implants and Orthopedics • More than 1,000 U.S. surgeons trained and 60,000 M6 - C artificial cervical discs implanted worldwide to date • Launched Opus Mg Set synthetic bone void filler • Submitted AccelStim PMA application for the healing of fresh fractures LEWISVILLE , Texas -- ( BUSINESS WIRE ) -- Orthofix Medical Inc. ( NASDAQ : OFIX ) today reported its financial results for the quarter ended September 30 , 2021. Net sales were $ 112 million , earnings per share ( " EPS " ) was $ ( 0.11 ) , and adjusted EPS was $ 0.10 . " I am proud of the tenacity of our team as they continue to implement our strategic initiatives despite the ongoing challenges of COVID , delivering double - digit growth in both our global Spinal Implants and Orthopedics businesses , " said Orthofix President and Chief Executive Officer Jon Serbousek . " New products remain a growth driver in the business . The strong adoption of the M6 - CTM artificial cervical disc continues as we recently passed the 60,000 worldwide implant mark , and sales of our FITBONE ™ limb - lengthening system have accelerated throughout the year , resulting in third quarter revenue growing 30 percent sequentially . " " As we close out the year , we will be focused on driving top - line performance and exiting the year with mid - single digit growth . We expect this accelerated growth in the near term to come from the continued strength of the M6 - C disc , the FITBONE system , and our recently bolstered 3D - printed titanium spinal interbody portfolio , " continued Serbousek . " Over the long term , we have multiple initiatives in place , including diversification of our biologics portfolio with products like Opus ™ Mg Set synthetic bone void filler and the planned expansion of our bone growth therapy portfolio with the AccelStim ™ ultrasound bone healing therapy for the healing of fresh and nonunion fractures . We anticipate the recent PMA application will allow us to bring this innovative offering and new indication to market in 2022. " Financial Results Overview 1